Designing Drug Candidatesat the Atomic Level
We integrate the fundamental principles of physics with advanced AI to design proteins, antibodies, peptides, and small molecules with atomic precision.
Physics-Informed AI
for Atomic-Level
Drug Discovery
The essence of drugs is atomic interactions. By learning 3D structure and physical interactions of atoms, our Hybrid AI addresses every drug modality, from small molecules to antibodies.
What makes our AI unique?
Conventional AI drug design relies solely on data patterns. Arontier's Hybrid AI fuses physics-based energy functions with graph neural networks, giving us predictive power even when experimental data is scarce.
Physics-Based Energy Function
Stable predictions grounded in physical laws, reliable even with minimal experimental data.
Graph Neural Network
Learns 3D structural features and interaction patterns from molecular graphs.
Continuous Learning Loop
Experimental feedback continuously refines model predictions for your specific target.
Multi-Modality Coverage
One platform for small molecules, peptides, proteins, antibodies, and more.
End-to-end drug discovery,
from target to candidate.
Three core services covering every stage, from large-scale virtual screening to experimentally validated biologics hits.
Trusted by leading pharma & biotech companies
Recent updates
Partnerships, investments, and platform milestones.
Get Started
Ready to Accelerate Your Program?
Whether you're exploring a new target or optimizing a lead, Arontier's AI platform can help you move faster with higher confidence.